---
title: "Iterum outlines ORLYNVAH's market potential with exclusivity through 2034"
date: "2025-02-07 18:20:46"
summary: "Earnings Call Insights: Iterum Therapeutics (NASDAQ:ITRM) Q4 2024 Management View CEO Corey Fishman emphasized 2024 as a pivotal year, highlighting the FDA approval of ORLYNVAH, the first and only oral penem in the U.S. for uncomplicated urinary tract infections (uUTIs). He noted ORLYNVAH's potential to fill a significant unmet need..."
categories:
  - "seekalpha"
lang:
  - "en"
translations:
  - "en"
tags:
  - "seekalpha"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Earnings Call Insights: Iterum Therapeutics (NASDAQ:[ITRM](https://seekingalpha.com/symbol/ITRM "Iterum Therapeutics plc")) Q4 2024

### Management View

* CEO Corey Fishman emphasized 2024 as a pivotal year, highlighting the FDA approval of ORLYNVAH, the first and only oral penem in the U.S. for uncomplicated urinary tract infections (uUTIs). He noted ORLYNVAH's potential to fill a significant unmet need in the market, particularly for patients with limited or no alternative oral antibacterial options.
* Fishman described the substantial market opportunity for ORLYNVAH, citing an estimated 40 million annual U.S. prescriptions for uUTIs and resistance rates of existing treatments reaching 20%-30%. He underscored that ORLYNVAH could be a critical option for elevated-risk patients, including women over 65, those with diabetes, recurrent infections, or other comorbidities.
* Fishman announced that ORLYNVAH benefits from 10 years of market exclusivity under the GAIN Act, extending to October 2034, and additional patent protection into 2039. He highlighted ongoing strategic efforts to sell, license, or commercialize the product while evaluating pre-commercialization activities.
* CFO Judy Matthews detailed operating expenses of $3.7 million in Q4 and $18.7 million for the full year, a decrease primarily attributed to the completion of the REASSURE trial. She added that cash and equivalents totaled $24.1 million at year-end, sufficient to fund operations into the second half of 2025.

### Outlook

* Management reiterated their focus on driving value through strategic alternatives for ORLYNVAH, including potential sales or licensing agreements. Fishman revealed outreach efforts to dozens of companies, including pharmaceutical and financial entities, to explore partnerships.
* Pre-commercialization activities are underway, with research targeting payer and physician insights and analytics around geography and patient demographics. These efforts aim to facilitate either a direct or partnered launch.
* Fishman stressed that while strategic transactions are prioritized, the company is prepared to pursue commercialization independently if necessary, subject to raising sufficient capital.

### Financial Results

* Q4 operating expenses decreased significantly year-over-year, reflecting the conclusion of the REASSURE trial. Research and development costs fell to $1.3 million in Q4, driven by trial completion, while general and administrative costs rose slightly to $2.1 million due to higher legal fees.
* Iterum reported a net loss of $6.6 million for Q4 and $24.8 million for full-year 2024. On a non-GAAP basis, the net loss was $3.1 million for Q4 and $17.6 million for the year, showing a substantial reduction from 2023 levels.
* The company repaid principal and interest on its exchangeable notes in January 2025 and deferred a $20 million milestone payment to Pfizer, accruing 8% annual interest, until October 2026.

### Q&A

* Thomas Yip, H.C. Wainwright: Asked about ongoing discussions with potential partners and types of entities involved. Fishman responded that outreach included both pharma companies and financial investors but declined to provide specifics, citing ongoing negotiations.
* Yip also inquired about pre-commercialization activities. Fishman explained efforts include payer and physician research and targeting analytics to prepare for a potential launch.
* Jason McCarthy, Maxim Group: Asked about the potential for international expansion and additional trials. Fishman indicated that while the current FDA data package suffices for the EU, additional studies would be required in China and Japan for approval.
* McCarthy followed up on the possibility of expanding ORLYNVAH's use to complicated UTIs. Fishman acknowledged interest from potential partners and expressed confidence in designing a successful trial for this indication.

### Sentiment Analysis

* Analysts expressed interest in the strategic direction but maintained a cautious tone regarding potential partnerships and commercialization efforts. Questions focused on the scope of ongoing discussions and the feasibility of additional trials.
* Management maintained a confident tone, especially regarding ORLYNVAH's market potential and exclusivity protections. Fishman emphasized the strategic importance of the uUTI market and Iterum's preparedness for commercialization.
* Compared to the previous quarter, management's tone was more focused on strategic alternatives and pre-commercial preparations, reflecting progress in their planning efforts.

### Quarter-over-Quarter Comparison

* The current quarter saw a shift in focus toward pre-commercialization and strategic alternatives for ORLYNVAH, compared to the prior quarter's emphasis on FDA approval and exclusivity.
* Analysts consistently questioned the company's strategic roadmap, but the tone shifted slightly from regulatory achievements to commercialization prospects.
* Managementâ€™s confidence remained steady, supported by ORLYNVAH's approval and the market's unmet needs. However, discussions on funding and partnership options introduced a degree of caution.
* Financial metrics showed reduced operating expenses and losses due to the conclusion of the REASSURE trial, aligning with prior expectations.

### Risks and Concerns

* Management highlighted uncertainties around the strategic transaction outcomes, noting that they cannot guarantee favorable terms or successful completion.
* Analysts raised concerns about additional trials needed for international expansion and the financial feasibility of independent commercialization.
* Iterum must manage cash resources carefully, with funding expected to last into the second half of 2025, and a $20 million deferred payment to Pfizer accruing interest.

### Final Takeaway

Iterum Therapeutics marked a transformative year with the FDA approval of ORLYNVAH, presenting a significant opportunity in the underserved uUTI market. Management is actively pursuing strategic alternatives to maximize value while preparing for potential commercialization. With strong market exclusivity and patent protections, ORLYNVAH is positioned to meet critical unmet needs, though uncertainties around partnerships and funding remain key considerations for stakeholders.

[Read the full Earnings Call Transcript](https://seekingalpha.com/symbol/ITRM/earnings/transcripts)

[seekalpha](https://seekingalpha.com/news/4405166-iterum-outlines-orlynvahs-market-potential-with-exclusivity-through-2034)
